NewAmsterdam Pharma(NAMSW)
NARRDEN, NetherlandsPharmaceutical
Focus: NewAmsterdam Pharma is a public small-molecule pharmaceutical company focused on metabolic, cardiovascular, and neurological diseases with a pipeline concentrated on the CETP inhibitor obicetrapib. The company is early-to-mid stage with minimal commercial revenue and heavy R&D investment.
Profile data last refreshed 6h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Total Funding
$196M
Open Jobs
7-1 this month
Stable — net -1 jobs in 30d
4 added, 5 removed. Backfill posture.
Should You Work at NewAmsterdam Pharma?
AI assessmentNewAmsterdam is a high-risk, high-reward opportunity for those seeking late-stage clinical impact in a capital-constrained environment where execution velocity is critical.
Why Work Here
- Pipeline depth: 20 active trials across Phase 1–3 with 6 Phase 3 programs in dyslipidemias and cardiovascular disease, offering exposure to late-stage clinical decision-making
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
6 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$14M
Key Products
Growing
Growth
Lead asset in Phase 3 development for dyslipidemia and cardiovascular indications; being tested in combination with ezetimibe and evolocumab.
Pipeline & Clinical Trials
Help build intelligence for NewAmsterdam Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.